

**CURRICULUM
VITAE**

**PERSONAL
INFORMATION**

First name / Surname Andrea Necchi
 Address(es) Vita-Salute San Raffaele University, Department of Medical Oncology – IRCCS San Raffaele Hospital, Milan
 Via Olgettina 60 – Milan – ITALY.
 Telephone(s) +39022643.1
 Fax +39022643.1
 Email necchi.andrea@hsr.it
 Nationality Italian
 Tax code NCCNDR79E09M052N
 Date of birth 09 May 1979
 Twitter handle @AndreaNecchi (Followers: 1523)

PERSONAL SKILLS

Mother tongue Italian
 Other language English
 Reading and understanding: Excellent
 Writing: Excellent
 Speaking: Excellent

CLINICAL ACTIVITY

11/2020 - Present Associate Professor
 Vita-Salute San Raffaele University
 Chief of Genitourinary Medical Oncology – IRCCS San Raffaele Hospital and Scientific Institute

03/2011 – 10/2020 Full staff medical oncologist
 Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
 Head of a clinical research group focused on urothelial cancers, germ-cell tumors, penile squamous-cell carcinoma.
 Principal investigator in phase I, II, III studies.
 Clinical activity: genitourinary medical oncology, with a primary focus on the following diseases:

- urothelial carcinoma (all stages)
- germ-cell tumors (all stages)
- penile squamous-cell carcinoma (locally-advanced or metastatic disease)
- other rare GU tumors (urethral carcinoma, variant histologies of the urinary tract) (all stages)

22-5-2017 BLS-D certificate.

**EDUCATION AND
TRAINING**

2005-2008 Postdoctoral Specialization in Medical Oncology (70/70 cum laude), Università degli Studi di Milano. Division of Hematologic Oncology – Lymphoma Unit (Prof. Alessandro M. Gianni).

1998-2004 Doctor of Medicine (110/110 cum laude), Università degli Studi di Milano.

1993-1998 High-school degree (60/60 cum laude), Liceo Scientifico “M.G. Agnesi”, Merate (LC), Italy.

Organisational / managerial skills and positions	<ul style="list-style-type: none"> - Vice-President and co-funder, Global Society of Rare Genitourinary Tumors (GSRGT) – www.gsrgt.com. - Board Member, European Association of Urology – Research Foundation (EAU-RF), since 2017 - Faculty member, Genitourinary Cancers, European Society for Medical Oncology (ESMO), since 2015 - Faculty member, ESMO Oncology Pro Working Group (ESMO-OPWG), 2015-2018 - Member of the EAU Young Academic Urologists (EAU-YAU) group, since 2015 - Member of the Penile Cancer Guidelines Panel of the EAU, since 2013 - Treasurer and Member of the Executive Committee, EORTC Genitourinary Cancers Group, 2013-2019
Honors and Awards	<ul style="list-style-type: none"> - Plenary Speaker, European Association of Urology (EAU) annual meeting, Barcelona, Spain, 15-19 March 2019. - 2018, 2019: 2 Merit Awards by the European Society for Medical Oncology (ESMO). - 2018: Reviewer of the Month & Reviewer of the Year for European Urology (2018 IF: 17.298) - 05/2012, 09/2012, 02/2013, 02/2015: 4 Merit Awards by the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). - 07/2011: 1st Gianni Bonadonna Prize for New Drug Development in Oncology, by the Michelangelo Foundation, Milano, Italy. - 11/2010: Young Researchers Award by the Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. - 2010: ESMO Translational Unit Visit (TRU Visit), Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
Board Certifications	<ul style="list-style-type: none"> - Italian Board of Medical Oncology, since 2008 - European Certification in Medical Oncology (ESMO), since 2006
Faculty position Planning committees and Scientific Committees (2018 onwards)	<ul style="list-style-type: none"> - ASCO (American Society of Clinical Oncology) annual meeting - Genitourinary Cancers Symposium - ESMO (European Society for Medical Oncology) annual meeting - EMUC (European Multidisciplinary Urologic Meeting) annual meeting - EAU (European Association of Urology) annual meeting - AUA (American Urological Association) annual meeting - SUO (Society of Urologic Oncology) annual meeting - SIU (Société Internationale d'Urologie) annual meeting
Membership in Pharmaceutical Company advisory boards – conflicts of interest (as of March 4 th , 2020)	<ul style="list-style-type: none"> - <u>Consulting</u>: Merck, Astra Zeneca, Janssen, Incyte Biosciences Inc., Roche, Rainier Therapeutics, Clovis Oncology, Bayer, and Astellas/Seattle Genetics, Ferring, Immunomedics. <u>Grant/Research support (Institution)</u>: Millennium-Takeda, Glaxo-Smith-Kline, Merck, Ipsen, and Astra Zeneca. <u>Travel expenses/Honoraria</u>: Roche, Merck, Astra Zeneca, and Janssen. - Since 2016 - Member of the Global Genitourinary Cancers Advisory Board of Merck Inc. - Since 2017 - Member of the Global Immuno-Oncology Steering Committee of Astra Zeneca. - Since 2018 - Member of the Incyte Council on Investigational Compounds (ICONIC) of Incyte Inc. - Member of the international steering committee of 6 phase 2 and phase 3 clinical trials in muscle-invasive and metastatic urothelial carcinoma: NILE (NCT03682068); Fight-205 (NCT04003610); THOR (NCT03390504); FIDES-02 (NCT04045613); ENERGIZE (NCT04209114); Keynote-905 (NCT03924895). - European principal investigator of the phase 2 trial fight-201 (Incyte), a multinational trial of pemigatinib, a pan-FGFR TKI, in refractory urothelial carcinoma (NCT02872714). - Member of the Independent Data Monitoring Committee (IDMC), ALBAN study (NCT03799835, Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients). Sponsor: Unicancer, France. Since 2019.

- Editorial Board Membership
- European Urology (2018 IF: 17.298): consulting editor, since 2019
 - European Urology Oncology: member of the editorial board at large
 - Current Opinion in Urology (2018 IF: 2.056)
 - Tumori Journal (TJ) (2018 IF: 1.234): associate editor

TEACHING ACTIVITY

- Associate Professor, Vita-Salute San Raffaele University, Milan, Italy. Since 2020.
- Adjunct Professor of medical oncology, University of Milan School of Medicine, School of Specialization in Medical Oncology, Milan. Since 2019.
- Faculty member, EAU Update on bladder cancer (BCa), since 2018.
- Faculty member, Global Congress on Bladder Cancer, since 2019.
- Faculty member, European School of Urology (ESU) course on immunotherapy for urologic tumors, held during the EAU annual meeting, since 2017.
- Faculty member, European School of Urology (ESU) course "Update on uro-oncology", held during the national congress of the Turkish Association of Urology. Girna (CY), 13 October 2017.
- Faculty member, American Urological Association (AUA) Instructional Course on Penile cancer, held during the annual meeting of AUA, since 2018.
- Co-relator of MD degree thesis: "Towards a noninvasive identification of tumor response to neoadjuvant pembrolizumab in muscle-invasive urothelial bladder cancer (MIBC): translational imaging findings from the PURE-01 study". Academic year 2018-2019, July 2019. Author: Donato Cannoletta. Vita-Salute San Raffaele University, Milan, Italy.
- Co-relator of MD degree thesis: "Preoperative pembrolizumab before radical cystectomy for muscle-invasive urothelial bladder carcinoma: interim clinical and biomarker findings from the phase II PURE-01 study". Academic year 2017-2018, July 2018. Author: Simone Luca Antonio Scuderi. Vita-Salute San Raffaele University, Milan, Italy.
- Co-relator of postgraduate thesis: "Nuovi bersagli di trattamento e meccanismi di resistenza ai farmaci antiangiogenetici: una strategia di sviluppo nelle neoplasie uroteliali". Academic year 2011-2012, April 2012. Author: Patrizia Giannatempo. University of Milan School of Medicine, Milan, Italy.
- Co-relator of postgraduate thesis: "A phase II study of neoadjuvant cisplatin and gemcitabine plus sorafenib for patients with transitional cell carcinoma of the bladder". Academic year 2012-2013, January 2014. Author: Daniele Raggi. University of Milan School of Medicine, Milan, Italy.

SCIENTIFIC ACTIVITY

- Publication metrics (as of March 4th, 2020)
- International indexed publications (Medline): 247
 - Total number of citations (Scopus): 7611
 - H-index (Scopus): 30
 - Book chapters: "Role of Neoadjuvant and Adjuvant chemotherapy in Penile Cancer". In A.S. Merseburger, M. Burger (eds), *Urologic Oncology*, Springer Nature Switzerland AG, 2019. https://doi.org/10.1007/978-3-3-319-42623-5_37.
- Best contribution to science
- My group pioneered the use of neoadjuvant immunotherapy in early-stage, muscle invasive disease, through the PURE-01 trial (Necchi A, et al. *J Clin Oncol* 2018). The study tested 3 cycles of neoadjuvant pembrolizumab prior to radical cystectomy. This study inspired several clinical trials that are currently being offered to patients in this clinical setting.
- Principal investigator of academic (investigator-initiated) studies & research grants recipient Years 2012-2019
- 2012: Research Grant (€ 109,750.30) by Millennium-Takeda for the investigator-initiated "Phase 2 study *"Brentuximab vedotin (SGN-35) as salvage therapy for males with advanced and platinum-resistant germ-cell tumors. An open-label, single-group, phase 2 trial"* (NCT01851200).
 - 2012: Research grant (€ 144,000.00) by GlaxoSmithKline for the investigator-initiated "Phase 2 study of single-agent Pazopanib for patients with relapsed or refractory germ-cell tumors (GCT)" (NCT01743482).

- 2013: Research Grant (€ 135,300,00) by the Scientific Directorate of Fondazione INT Milano for the collaborative research project with Memorial Sloan-Kettering Cancer Center “*Personalizing antiangiogenic treatment in advanced urothelial cancer*”.
 - 2013: Research grant (\$ 75,000.00) by Millennium-Takeda for the investigator-initiated “*Phase 2 study of the Aurora kinase A inhibitor Alisertib (MLN8237) in patients with relapsed or refractory transitional-cell carcinoma of the bladder and urothelial tract*” (NCT02109328).
 - 2016: Research grant (\$ 129,789.00) by Merck Inc. for the investigator-initiated study “An open label, single-arm, phase 2 study of pembrolizumab and nanoparticle albumin-bound paclitaxel in patients with metastatic urothelial carcinoma after chemotherapy failure; the PEANUT study” (NCT03464734).
 - 2017: Research grant (\$ 347,381.52) by Merck Inc. for the investigator-initiated study “PURE-01 – An open label, single-arm, phase 2 study of neoadjuvant pembrolizumab (MK-3475) before cystectomy for patients with muscle-invasive urothelial bladder cancer” (NCT02736266).
 - 2017: Research grant (\$ 100,950.52) by Astra Zeneca for the investigator-initiated study “An open label, single-group, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab (MEDI4736), alone or in combination with Tremelimumab, in patients with advanced and relapsed germ cell tumors” (NCT03081923).
 - 2017: Research grant (€ 50,000.00) by Ipsen for the investigator-initiated study “Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): an open-label, single-center, phase 2, single-arm trial” (NCT03943602).
 - 2017: My First AIRC Grant (MFAG) from the Italian Association of Cancer Research (AIRC): € 377,000.00 (MFAG 2017 Id 20617).
 - 2018: Research grant (€ 198,000.00) by Astra Zeneca + Ipsen for the investigator-initiated study “Cabozantinib plus durvalumab (Medi 4736) in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-of-concept trial” (NCT03824691).
 - 2019: Research grant (\$ 439,010.00) by Merck Inc. for the investigator-initiated study “A personalized approach of neoadjuvant immunotherapy and bladder preservation in localized, high-risk urothelial carcinoma of the bladder (Pericles study)” (trial identification number: TBD).
 - 2019: Research grant (\$ 1,477,716.00) by Incyte Inc. for the multicenter European investigator-initiated study “Open-label, single-arm, Phase II study, evaluating safety and efficacy of INCB054828 (pemigatinib) as adjuvant therapy for molecularly-selected, high-risk patients with urothelial carcinoma who have received radical surgery. A European Association of Urology Research Foundation Phase II Clinical Trial (NCT04294277).
- Academic collaborations/
partnerships
- 02/2020: Department of Defense (DoD)/CDMRP/PRCRP Idea Award with Special Focus 2019, titled: “Identifying biomarkers of response and resistance to immunotherapy in bladder cancer”. Collaborator: Cleveland Clinic Taussig Cancer Institute (P.I. Dr. Shilpa Gupta). Outcome: Funded.
 - 2019: Artificial Intelligence – Radiomics for prediction of response to immunotherapy in muscle-invasive urothelial bladder carcinoma. Collaborator: Netherlands Cancer Institute – Antoni van Leeuwenhoek University, Amsterdam (NL). Project ongoing.
 - 2019: AACR Bayer Innovation and Discovery Grants. Title of the project: Targeting FGF in bladder cancer after neoadjuvant immunotherapy and surgery. Collaborator: Prof. Joshua Meeks, Northwestern University, Chicago, IL, USA. Outcome: Funded.

Partnership with for-profit Companies	<ul style="list-style-type: none"> - Foundation Medicine, Cambridge, MA, United States. - Decipher Biosciences, Vancouver, Canada. - Celsius Therapeutics, Cambridge, MA, United States.
MENTORSHIP ACTIVITY	
Personal statement	I am leading a clinical and translational group dedicated to the genitourinary malignancies, with a primary focus on urothelial cancer, germ-cell tumors and penile squamous-cell carcinoma. The budget of my group currently affords three attending clinical oncologists, one post-doc research fellow, two junior data managers, one senior study coordinator, and one research nurse.
Honors and awards of young collaborators	<ul style="list-style-type: none"> - 2013: Patrizia Giannatempo was selected for the prestigious "15th joint ECCO-AACR-EORTC-ESMO Workshop 'Methods in Clinical Cancer Research' Waldhaus Flims, Switzerland, 22 – 28 June 2013". - 2015: Patrizia Giannatempo was the recipient of Merit Award by the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). - 2015: Daniele Raggi was the recipient of Merit Award by the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). - 2019 and 2020: Marco Bandini was the recipient of Merit Award by the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO).
Mentor in international fellowships	<ul style="list-style-type: none"> - 2014-2018: Mentor of international young oncologists within the ESMO Clinical Unit Visits programme: Drs. Karima Oualla (Morocco), Fatjona Kraja (Albania), Bohdan Bidovanets (Ukraine).
PATIENT ADVOCATES SUPPORT	
	<ul style="list-style-type: none"> - Co-author of the 2016 European Cancer Patient Coalition (ECPC) White Paper of Bladder cancer (http://www.ecpc.org/Documents/Policy&Advocacy/ECPC%20initiatves/07_04_16_bladdercancer_interactive.pdf). - Co-founder and secretary of PaLiNUro (Pazienti Liberi dalle Neoplasie Uroteliali, www.associazionepalinuro.com).
MEDIA COVERAGE	
2019	Video interview with Alicia Morgans by UroToday: Neoadjuvant Treatment in Muscle Invasive Bladder Cancer: https://www.urotoday.com/video-lectures/advanced-bladder-cancer/video/1238-embedded-media2019-04-11-14-00-18.html .
2019	Video roundtable by ecancer: Expert to Expert Interview, Key Developments in Urothelial Cancer at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, IL, United States: https://ecancer.org/en/video/7923-novel-therapies-in-the-treatment-of-bladder-cancer .
2019	Video interview by Touch Oncology: ESMO 2019 - KEYNOTE-045 trial in advanced urothelial cancer: https://www.youtube.com/watch?v=NUejT4om7Dc .
2019	Video roundtable by ecancer: ASCO GU 2019: Updates on treatment and management of bladder cancer: https://ecancer.org/en/video/7695-asco-gu-2019-updates-on-treatment-and-management-of-bladder-cancer .
2017	Video interview by OncliveTV: Impact of PD-1 Inhibition in Bladder Cancer: https://www.youtube.com/watch?v=i4DjbAqF2kl .
2016	2016 Genitourinary Cancers Symposium coverage by ecancer: Alisertib for pretreated urothelial cancer: https://ecancer.org/en/video/4538-alisertib-for-pretreated-urothelial-cancer .
2016	2016 Genitourinary Cancers Symposium coverage by ecancer: Brentuximab vedotin as salvage therapy for men with relapsed germ-cell tumours:

2012 | <https://ecancer.org/en/video/4533-brentuximab-vedotin-as-salvage-therapy-for-men-with-relapsed-germ-cell-tumours>.
AACR 2012 Press Conference, broadcasted by ecancer: Biomarker identified in relation to pazopanib in refractory urothelial cancer:
<https://ecancer.org/en/video/1343-biomarker-identified-in-relation-to-pazopanib-in-refractory-urothelial-cancer>.

OTHER INTERESTS

- Member of the Rotary Club “Milano Nord”, 2040th District of Rotary International.

Place and Date | Milano, 30/10/2020